Lisdexamfetamine Shortage: What Providers and Prescribers Need to Know in 2026

Provider Briefing: The Lisdexamfetamine Supply Situation in 2026

The Lisdexamfetamine (Vyvanse) shortage has been one of the most disruptive medication access challenges in recent years, and it continues to affect clinical practice heading into 2026. As a prescriber, you're likely fielding calls from patients who can't fill their prescriptions, adjusting treatment plans on the fly, and navigating a complex landscape of supply constraints, regulatory limits, and insurance barriers.

This briefing covers the current state of the shortage, its clinical implications, and practical strategies to support your patients.

Timeline: How We Got Here

Understanding the timeline helps contextualize the current situation:

• October 2022: The FDA formally acknowledged a shortage of amphetamine mixed salts (Adderall), which quickly expanded to include Lisdexamfetamine and other stimulant medications
• February 2023: Takeda's patent on Vyvanse expired, opening the door for generic Lisdexamfetamine
• Mid-2023: The FDA approved multiple generic manufacturers, but initial production volumes were insufficient to meet demand
• 2024: Over 15 generic manufacturers were producing Lisdexamfetamine, yet intermittent shortages persisted across multiple strengths
• September 2025: The DEA raised the aggregate production quota (APQ) for Lisdexamfetamine by approximately 24%
• October 2025: Additional DEA quota increases of up to 25% were approved for key ADHD stimulant ingredients heading into 2026
• February 2026: ASHP continues to list generic Lisdexamfetamine capsules as in shortage. Brand Vyvanse is generally available but at significantly higher cost.

Prescribing Implications

The shortage creates several clinical considerations for providers:

Treatment Continuity

Patients who have been stable on Lisdexamfetamine may face gaps in therapy when they can't fill their prescriptions. Abrupt discontinuation of stimulant medication doesn't cause dangerous withdrawal, but patients typically experience a return of ADHD or BED symptoms — which can affect work, school, relationships, and safety (particularly for patients whose ADHD affects driving or other high-stakes activities).

Dose Flexibility

Not all strengths are equally affected. If your patient takes 60 mg or 70 mg daily, consider whether prescribing two lower-strength capsules (e.g., two 30 mg capsules for a 60 mg dose) might improve their chances of finding the medication in stock. This requires clear patient education to avoid dosing errors.

Formulation Options

Lisdexamfetamine is available as both capsules (10-70 mg) and chewable tablets (10-60 mg). The chewable formulation is often less affected by shortages. Switching formulations may help patients maintain access without changing the medication itself.

Generic vs. Brand Considerations

Brand Vyvanse from Takeda remains generally available but costs $300-$400/month without insurance. For patients with adequate insurance coverage or financial means, prescribing brand-name Vyvanse may be a reliable option. For others, navigating generic availability requires patience and flexibility.

Current Availability Picture

As of early 2026, the availability landscape looks like this:

• Brand Vyvanse (Takeda): Generally available across most pharmacies
• Generic capsules: Variable availability. Some manufacturers (Teva, Sandoz, Amneal) have improved supply, while others report ongoing constraints. Availability varies by region and strength.
• Generic chewable tablets: More consistently available than capsules in many markets
• Most-affected strengths: 50 mg, 60 mg, and 70 mg capsules tend to be hardest to find; lower strengths (10-30 mg) are generally more available

40,272+ patients found their medications in stock

40K+

Find Lisdexamfetamine In Stock Today →

Cost and Access Considerations

Cost remains a significant barrier, particularly for uninsured or underinsured patients:

• Generic with discount coupon (GoodRx, SingleCare): $60-$70/month
• Generic retail without coupon: $200-$360/month
• Brand Vyvanse without insurance: $300-$400/month
• Insurance copays: Typically $20-$75, but prior authorization is increasingly common

Patient assistance programs: Takeda's Help at Hand program (helpathandpap.com) may provide brand Vyvanse to uninsured patients who meet income criteria. NeedyMeds and RxAssist maintain updated directories of additional assistance programs.

For a patient-facing resource on saving money, you can direct patients to our guide on Lisdexamfetamine cost savings.

Tools and Resources for Your Practice

Medfinder for Providers

Medfinder offers pharmacy availability data that can help your team identify which pharmacies currently have Lisdexamfetamine in stock. This can be integrated into your workflow when writing prescriptions — check availability before sending the script to a specific pharmacy.

Alternative Medication Reference

When Lisdexamfetamine is unavailable, common therapeutic alternatives include:

• Adderall XR (Mixed Amphetamine Salts ER): Same drug class, similar duration. Approximate dose equivalency: Lisdexamfetamine 70 mg ≈ Adderall XR 20-30 mg (individual titration recommended).
• Concerta (Methylphenidate ER): Different stimulant class. May be appropriate for patients open to trying a methylphenidate-based medication.
• Dexedrine/Dextroamphetamine ER: Contains the same active metabolite as Lisdexamfetamine. Available in IR and ER formulations.
• Atomoxetine (Strattera): Non-stimulant option. Not subject to Schedule II restrictions. Slower onset (4-6 weeks to full effect).

For a more detailed comparison, see our clinical guide on helping patients find Lisdexamfetamine.

Prior Authorization Tips

If patients need to switch to an alternative that requires PA, document the shortage as the reason for the medication change. Most payers have streamlined PA processes for shortage-related switches, and citing the ASHP shortage listing can expedite approval.

Skip the calls, skip the stress.

Find Lisdexamfetamine In Stock Today →

50K+

Medications
Found

99%

Success
Rate

6+

Hours saved
on average

Looking Ahead

The combination of DEA quota increases and expanded generic manufacturing capacity should gradually stabilize Lisdexamfetamine supply through 2026. However, the structural factors driving the shortage — rising ADHD diagnoses, controlled substance production limits, and complex supply chains — are unlikely to resolve overnight.

Providers can expect:

• Gradual improvement in generic availability, particularly in the second half of 2026
• Continued regional variability in supply
• Potential for future quota adjustments if demand continues to outpace supply
• Ongoing need for clinical flexibility in treatment planning

Final Thoughts

The Lisdexamfetamine shortage is a systems-level problem, but its impact is felt one patient at a time. Staying informed about the supply landscape, maintaining flexibility in prescribing, and leveraging tools like Medfinder can help you keep patients on effective treatment even during a challenging period.

For more provider-focused resources, see our guide on how to help patients find Lisdexamfetamine in stock and our provider's guide to helping patients save money on Lisdexamfetamine.